MA29404B1 - Preparation pharmaceutique - Google Patents
Preparation pharmaceutiqueInfo
- Publication number
- MA29404B1 MA29404B1 MA30318A MA30318A MA29404B1 MA 29404 B1 MA29404 B1 MA 29404B1 MA 30318 A MA30318 A MA 30318A MA 30318 A MA30318 A MA 30318A MA 29404 B1 MA29404 B1 MA 29404B1
- Authority
- MA
- Morocco
- Prior art keywords
- pharmaceutical preparation
- aberrational
- pkt
- activity
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
L'INVENTION PORTE SUR UNE PRÉPARATION PHARMACEUTIQUE ORALE CONTENANT DES SELS DITOSYLATE DE 4-QUINAZOLINEAMINES ET SUR LEURS MÉTHODES D'UTILISATION POUR LE TRAITEMENT DE TROUBLES CARACTÉRISÉS PAR UNE ACTIVITÉ ABERRANTE DE LA PKT DE LA FAMILLE ERBB.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US67280505P | 2005-04-19 | 2005-04-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA29404B1 true MA29404B1 (fr) | 2008-04-01 |
Family
ID=37115487
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA30318A MA29404B1 (fr) | 2005-04-19 | 2007-10-25 | Preparation pharmaceutique |
Country Status (28)
Country | Link |
---|---|
US (3) | US8821927B2 (fr) |
EP (1) | EP1871347B1 (fr) |
JP (1) | JP5202302B2 (fr) |
KR (1) | KR101356748B1 (fr) |
CN (1) | CN101203211B (fr) |
AR (1) | AR054252A1 (fr) |
AU (1) | AU2006236423B2 (fr) |
BR (1) | BRPI0609962B1 (fr) |
CA (1) | CA2606207C (fr) |
CY (1) | CY1118179T1 (fr) |
DK (1) | DK1871347T3 (fr) |
EA (1) | EA200702253A1 (fr) |
ES (1) | ES2601503T3 (fr) |
HR (1) | HRP20161429T1 (fr) |
HU (1) | HUE030982T2 (fr) |
IL (1) | IL186336A0 (fr) |
LT (1) | LT1871347T (fr) |
MA (1) | MA29404B1 (fr) |
MX (1) | MX2007013089A (fr) |
NO (1) | NO20075111L (fr) |
NZ (1) | NZ562223A (fr) |
PE (1) | PE20061430A1 (fr) |
PL (1) | PL1871347T3 (fr) |
PT (1) | PT1871347T (fr) |
SI (1) | SI1871347T1 (fr) |
TW (1) | TW200716204A (fr) |
WO (1) | WO2006113649A1 (fr) |
ZA (1) | ZA200708705B (fr) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2606207C (fr) * | 2005-04-19 | 2014-11-18 | Smithkline Beecham (Cork) Limited | Preparation pharmaceutique |
US8252805B2 (en) | 2008-05-07 | 2012-08-28 | Teva Pharmaceutical Industries Ltd. | Forms of lapatinib ditosylate and processes for preparation thereof |
EP2158913A1 (fr) | 2008-08-25 | 2010-03-03 | Ratiopharm GmbH | Composition pharmaceutique comportant de la N-[3-chhloro-4-[3-fluorophenyl)methoxy)phenyl]6-[5[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furyl]-4-quinazolinamine |
EP2158912A1 (fr) * | 2008-08-25 | 2010-03-03 | Ratiopharm GmbH | Composition pharmaceutique comportant de la N-[3-chhloro-4-[3-fluorophenyl)methoxy)phenyl]6-[5[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furyl]-4-quinazolinamine |
WO2010099150A1 (fr) * | 2009-02-24 | 2010-09-02 | Smithkline Beecham (Cork) Limited | Comprimé pharmaceutique et procédé |
US20120245351A1 (en) * | 2009-09-29 | 2012-09-27 | Natco Pharma Limited | Process for the preparation of lapatinib and its pharmaceutically acceptable salts |
US20130072507A1 (en) | 2010-05-21 | 2013-03-21 | Glaxosmithkline Llc | Combination |
ES2530755T3 (es) | 2010-05-21 | 2015-03-05 | Glaxosmithkline Llc | Terapia de combinación para el tratamiento del cáncer |
US9907767B2 (en) | 2010-08-03 | 2018-03-06 | Velicept Therapeutics, Inc. | Pharmaceutical compositions and the treatment of overactive bladder |
PE20131341A1 (es) | 2010-08-03 | 2013-12-07 | Altherx Inc | Combinaciones de agonistas del receptor beta-3-adrenergico y antagonistas del receptor muscarinico para tratar vejiga hiperactiva |
CN104981235A (zh) * | 2013-02-19 | 2015-10-14 | 赫克萨尔股份公司 | 包括n-[3-氯-4-(3-氟苄氧基)苯基]-6-[5({[2-(甲基磺酰基)乙基]氨基}甲基)-2-呋喃基]喹唑啉-4-胺或其药学可接受的盐、溶剂化物或溶剂化盐的药物组合物 |
WO2014170910A1 (fr) | 2013-04-04 | 2014-10-23 | Natco Pharma Limited | Procédé de préparation du lapatinib |
US9636340B2 (en) | 2013-11-12 | 2017-05-02 | Ayyappan K. Rajasekaran | Kinase inhibitors |
WO2016090168A1 (fr) | 2014-12-03 | 2016-06-09 | Velicept Therapeutics, Inc. | Compositions et procédés d'utilisation du solabégron à libération modifiée pour traiter des symptômes du bas appareil urinaire |
CN106389373B (zh) * | 2015-07-29 | 2019-07-02 | 四川科伦药物研究院有限公司 | 一种二甲苯磺酸拉帕替尼片剂及其制备方法 |
CN106511289A (zh) * | 2015-09-10 | 2017-03-22 | 湖北生物医药产业技术研究院有限公司 | 甲苯磺酸拉帕替尼片剂及其制备方法 |
IL258856B2 (en) | 2015-10-23 | 2024-07-01 | Velicept Therapeutics Inc | Zwitterion solvegron and its uses |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5506248A (en) * | 1993-08-02 | 1996-04-09 | Bristol-Myers Squibb Company | Pharmaceutical compositions having good dissolution properties |
GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
KR100520401B1 (ko) | 1997-04-25 | 2005-10-12 | 얀센 파마슈티카 엔.브이. | 파네실 트랜스퍼라제 억제작용을 갖는 퀴나졸리논 |
TW436485B (en) | 1997-08-01 | 2001-05-28 | American Cyanamid Co | Substituted quinazoline derivatives |
GB9800569D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
JP4102185B2 (ja) * | 2000-06-30 | 2008-06-18 | グラクソ グループ リミテッド | キナゾリンジトシル酸塩化合物 |
AU2002236765A1 (en) | 2001-01-16 | 2002-07-30 | Glaxo Group Limited | Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent |
US20050176740A1 (en) | 2002-04-08 | 2005-08-11 | Spector Neil L. | Cancer treatment method comprising administering an erb-family inhibitor and a raf and/or ras inhibitor |
WO2004000094A2 (fr) * | 2002-06-19 | 2003-12-31 | Smithkline Beecham Corporation | Marqueurs predictifs utilises dans le traitement du cancer |
CA2606207C (fr) * | 2005-04-19 | 2014-11-18 | Smithkline Beecham (Cork) Limited | Preparation pharmaceutique |
-
2006
- 2006-04-18 CA CA2606207A patent/CA2606207C/fr active Active
- 2006-04-18 PL PL06750475T patent/PL1871347T3/pl unknown
- 2006-04-18 MX MX2007013089A patent/MX2007013089A/es active IP Right Grant
- 2006-04-18 AR AR20060101526A patent/AR054252A1/es not_active Application Discontinuation
- 2006-04-18 US US11/911,843 patent/US8821927B2/en active Active
- 2006-04-18 SI SI200632109A patent/SI1871347T1/sl unknown
- 2006-04-18 HU HUE06750475A patent/HUE030982T2/en unknown
- 2006-04-18 WO PCT/US2006/014447 patent/WO2006113649A1/fr active Application Filing
- 2006-04-18 BR BRPI0609962-9A patent/BRPI0609962B1/pt active IP Right Grant
- 2006-04-18 JP JP2008507783A patent/JP5202302B2/ja active Active
- 2006-04-18 NZ NZ562223A patent/NZ562223A/en not_active IP Right Cessation
- 2006-04-18 EP EP06750475.3A patent/EP1871347B1/fr active Active
- 2006-04-18 PT PT67504753T patent/PT1871347T/pt unknown
- 2006-04-18 LT LTEP06750475.3T patent/LT1871347T/lt unknown
- 2006-04-18 EA EA200702253A patent/EA200702253A1/ru unknown
- 2006-04-18 ES ES06750475.3T patent/ES2601503T3/es active Active
- 2006-04-18 KR KR1020077026740A patent/KR101356748B1/ko active IP Right Grant
- 2006-04-18 DK DK06750475.3T patent/DK1871347T3/en active
- 2006-04-18 CN CN2006800219417A patent/CN101203211B/zh active Active
- 2006-04-18 PE PE2006000406A patent/PE20061430A1/es not_active Application Discontinuation
- 2006-04-18 TW TW095113811A patent/TW200716204A/zh unknown
- 2006-04-18 AU AU2006236423A patent/AU2006236423B2/en not_active Revoked
-
2007
- 2007-10-07 IL IL186336A patent/IL186336A0/en unknown
- 2007-10-09 NO NO20075111A patent/NO20075111L/no not_active Application Discontinuation
- 2007-10-11 ZA ZA200708705A patent/ZA200708705B/xx unknown
- 2007-10-25 MA MA30318A patent/MA29404B1/fr unknown
-
2014
- 2014-07-28 US US14/444,637 patent/US20140335177A1/en not_active Abandoned
-
2016
- 2016-01-29 US US15/009,927 patent/US20160143909A1/en not_active Abandoned
- 2016-11-02 HR HRP20161429TT patent/HRP20161429T1/hr unknown
- 2016-11-03 CY CY20161101115T patent/CY1118179T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA29404B1 (fr) | Preparation pharmaceutique | |
MA31764B1 (fr) | Composés et compositions en tant que modulateurs de l'activité de gpr119 | |
MA27596A1 (fr) | Derives d'heteroarylamides benzocondenses de thienopyridines utiles comme agents therapeutiques, compositions pharmaceutiques les contenant et methodes pour leur utilisation | |
MA30324B1 (fr) | Benzimidazoles presentant une activite au niveau du recepteur m1 et leurs utilisations en medecine. | |
MA47447B1 (fr) | 2-hétéroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides pour le traitement du cancer | |
TNSN07021A1 (fr) | Derives de quinazoline -4-yl-piperidine et cinnoline -4-yl-piperidine servant d'inhibiteurs de pde10 pour le traitement de troubles du snc | |
MEP45308A (en) | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia | |
MA31373B1 (fr) | Composes amino-heterocycliques | |
MA27448A1 (fr) | Derives de pyridine modulateurs du recepteur cb2 | |
MA27438A1 (fr) | Piperazines heterocycliques substituees pour le traitement de la schizophrenie | |
TNSN04156A1 (fr) | Pyridinones substituees servant de modulateurs de la map-kinase p38 | |
MA30339B1 (fr) | Azolopyrimidines inhibitrices de l'activite du recepteur cannabinoïde 1 | |
MA31952B1 (fr) | Pyrrolopyrimidines et pyrrolopyridines | |
MA27568A1 (fr) | Derives de pyrrolopyrimidine | |
TNSN07063A1 (fr) | Utilisations therapeutiques d'inhibiteurs de rtp801 | |
MA33053B1 (fr) | Inhibiteurs de la poly(adp-ribose) polymerase (parp) | |
MA34474B1 (fr) | Agonistes de gpr40 | |
TNSN03130A1 (fr) | Inhibiteurs de protease du vih, compositions les contenant, leurs utilisations pharmaceutiques et matieres pour leur synthese | |
EA200700035A1 (ru) | Сульфаматные и сульфамидные производные для лечения эпилепсии и родственных di sorders | |
MA27661A1 (fr) | Indolone-oxazolidinones antibacteriennes, intermediaires pour leur preparation et compositions pharmaceutiques les contenant | |
BRPI0414864A (pt) | composição farmacêutica multiparticulada compreendendo ácido micofenólico ou micofenolato de sódio e combinação com rapamicida | |
MA46229B1 (fr) | Composés d'hétéroaryle carboxamide en tant qu'inhibiteurs de ripk2 | |
EA200701856A1 (ru) | Тетрагидропиридоазепин-8-оны и родственные соединения для лечения шизофрении | |
ATE312815T1 (de) | Neue verbindungen | |
DE602006009556D1 (de) | Chinolin-derivate zur behandlung von mglur5-rezeptor-vermittelten erkrankungen |